Neoantigen Targeted Therapies Market Target Indications (Bone And Cartilage Cancer, Colorectal Cancer, Head And Neck Cancer, Renal Carcinoma, Hepatocellular Carcinoma, Lung Cancer, Gynecological Cancer And Others), Type Of Treatment (Personalized And Off-The-Shelf), Type Of Immunotherapy (Dendritic Cell Vaccine, DNA / RNA-Based Vaccine, Protein / Peptide-Based Vaccine And TIL-Based Therapy), Route Of Administration (Intradermal, Intravenous, Subcutaneous, And Others) And Key Geographical Regions (US, UK, Germany, France, Italy, Spain And Rest Of The World), 2019-2030

May 2019 | 323 pages | ID: N7C13671161EEN
Roots Analysis

Abstracts

The global neoantigen targeted market is expected to reach USD 3 million by 2030 and anticipated to grow at a CAGR of 55% during the forecast period 2019-2030

Cancer poses a substantial global health challenge, accounting for 0.6 million deaths in the United States alone in 2018 and ranking as a leading cause of mortality worldwide. Projections from the World Health Organization suggest a staggering 70% increase in new cancer cases over the next two decades. While conventional treatments such as chemotherapy, surgery, and radiation therapy are prevalent, their effectiveness in advanced cancer stages remains notably limited. Furthermore, these therapies, due to their indiscriminate and highly toxic nature, significantly compromise patients’ quality of life.

Among various targeted anti-cancer therapies, immunotherapy has emerged as a promising approach. It demonstrates the potential to eliminate tumor cells while minimizing adverse effects. Notably, immune checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 inhibitors have provided lasting clinical benefits to individuals with metastatic tumors. However, these therapies show significant variability in eliciting immune responses among patients, resulting in only a fraction experiencing substantial benefits. Statistics indicate that nearly 70% of individuals treated with single-agent immune checkpoint therapy do not respond effectively.

Advancements in genomic analysis and bioinformatics have enabled more personalized treatment approaches, particularly in the realm of neoantigen-targeted therapies. Cancer neoantigens, representing antigens encoded by tumor-specific mutated genes previously unrecognized by the host’s immune system, offer promising biological targets to enhance the therapeutic efficacy of various cancer immunotherapies. These neoantigens have demonstrated the capacity to stimulate robust T-cell mediated immune responses, holding immense potential in augmenting immune checkpoint inhibitors and cancer vaccines. Currently, several investigational neoantigen-based therapies are under scrutiny alongside diverse immune checkpoint inhibitors such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Numerous initiatives led by start-ups, supported by venture capital firms and strategic investors, are dedicated to exploring and advancing these therapeutic avenues.

Report Coverage

• The report examines the neoantigen targeted therapies market across multiple parameters, including target indications, treatment types, immunotherapy forms, administration routes, and geographical regions.
• It thoroughly analyzes the factors influencing market growth—such as drivers, restraints, opportunities, and challenges.
• Evaluates the potential benefits and barriers within the market, providing insights into the competitive landscape for major market players.
• Projects revenue forecasts for market segments across various countries.
• Conducts a comprehensive assessment of the current cancer treatment market, including categorization based on development phases, molecule types, treatment approaches, therapy types, immunotherapy specifics, target indications, treatment lines, and drug administration methods.
• Offers detailed profiles of leading developers of neoantigen targeted therapies, focusing on their robust pipeline products, encompassing company overview, financial insights (if available), product portfolio, recent collaborations, and future projections.
• Analyzes around 300 scientific articles published between 2015 and early 2019, highlighting research trends in disease indications, associated cancer immunotherapies, publication types, years, and influential journals contributing to the neoantigen targeted therapies market during that timeframe.
• Conducts an in-depth examination of patents related to neoantigens up to April 2019, covering patent types, publication years, issuing authorities, assigned CPC symbols, emerging focuses, and major industry/academic entities with significant intellectual property portfolios in this field.
• Analyzes partnerships related to neoantigen targeting therapies established until March 2019, categorizing them by partnership types, years, targeted disease indications, immunotherapy modalities, and the most active entities involved in these collaborations.
• Assesses investments in companies focused on developing neoantigen targeted therapies, encompassing various financing forms such as seed financing, venture capital, debt financing, grants, initial public offerings (IPOs), and subsequent offerings at different developmental stages.

Key Market Companies

• Bavarian Nordic
• Genocea Biosciences
• Gradalis
• Immunicum
• Immunovative Therapies
• Iovance Biotherapeutics
• MediGene
• Neon Therapeutics

Contents

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
  3.5.1. Types of Neoantigens
  3.5.2. Role of Neoantigens in Cancer Immunotherapy
  3.5.3. Neoantigen Targeted Therapies
    3.5.3.1. Identification and Selection of Neoantigens
    3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives

4. MARKET OVERVIEW

4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline Analysis
  4.3.1. Analysis by Phase of Development
  4.3.2. Analysis by Type of Molecule
  4.3.3. Analysis by Type of Immunotherapy
  4.3.4. Analysis by Type of Therapy
  4.3.5. Analysis by Route of Administration
  4.3.6. Analysis by Target Disease Indication
  4.3.7. Analysis by Type of Neoantigen
  4.3.8. Analysis by Line of Therapy
  4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy
  4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration
4.4. Neoantigen Targeted Therapies: List of Drug Developers
  4.4.1. Analysis by Year of Establishment
  4.4.2. Analysis by Company Size and Geographical Location
  4.4.3. Leading Developers
  4.4.4. Analysis by Geography
4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location

5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES

5.1. Chapter Overview
5.2. Bavarian Nordic
  5.2.1. Company Overview
  5.2.2. Financial Information
  5.2.3. Neoantigen Targeted Therapies Portfolio
  5.2.4. Recent Collaborations
  5.2.5. Future Outlook
5.3. Genocea Biosciences
  5.3.1. Company Overview
  5.3.2. Financial Information
  5.3.3. Neoantigen Targeted Therapies Portfolio
  5.3.4. Recent Collaborations
  5.3.5. Future Outlook
5.4. Gradalis
  5.4.1. Company Overview
  5.4.2. Neoantigen Targeted Therapies Portfolio
  5.4.3. Recent Collaborations
  5.4.4. Future Outlook
5.5. Immunicum
  5.5.1. Company Overview
  5.5.2. Financial Information
  5.5.3. Neoantigen Targeted Therapies Portfolio
  5.5.4. Recent Collaborations
  5.5.5. Future Outlook
5.6. Immunovative Therapies
  5.6.1. Company Overview
  5.6.2. Neoantigen Targeted Therapies Portfolio
  5.6.3. Recent Collaborations
  5.6.4. Future Outlook
5.7. Iovance Biotherapeutics
  5.7.1. Company Overview
  5.7.2. Financial Information
  5.7.3. Neoantigen Targeted Therapies Portfolio
  5.7.4. Recent Collaborations
  5.7.5. Future Outlook
5.8. MediGene
  5.8.1. Company Overview
  5.8.2. Financial Information
  5.8.3. Neoantigen Targeted Therapies Portfolio
  5.8.4. Recent Collaborations
  5.8.5. Future Outlook
5.9. Neon Therapeutics
  5.9.1. Company Overview
  5.9.2. Financial Information
  5.9.3. Neoantigen Targeted Therapies Portfolio
  5.9.4. Recent Collaborations
  5.9.5. Future Outlook

6. PUBLICATION ANALYSIS

6.1. Chapter Overview
6.2. Methodology
6.3. Neoantigen Targeted Therapies: List of Publications
  6.3.1. Analysis by Year of Publication
  6.3.2. Analysis by Type of Study
  6.3.3. Analysis by Study Objective
  6.3.4. Analysis by Affiliated Therapies
  6.3.5. Analysis by Target Disease Indication
  6.3.6. Key Journals: Analysis by Number of Publications

7. PATENT ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Neoantigen Targeted Therapies: Patent Analysis
  7.3.1. Analysis by Publication Year
  7.3.2. Analysis by Geographical Location
  7.3.3. Analysis by CPC Classifications
  7.3.4. Analysis by Type of Industry
  7.3.5. Emerging Focus Areas
  7.3.6. Leading Players: Analysis by Number of Patents
7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
  7.4.1. Analysis by Patent Characteristics
7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations
  8.3.1. Analysis by Year of Partnership
  8.3.2. Analysis by Type of Partnership
  8.3.3. Analysis by Type of Immunotherapy
  8.3.4. Analysis by Type of Partnership and Type of Product
  8.3.5. Analysis by Type of Partnership and Target Disease Indication
  8.3.6. Regional Analysis
  8.3.7. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview
9.2. Types of Funding
9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
  9.3.1. Analysis by Number of Instances
  9.3.2. Analysis by Amount Invested
  9.3.3. Analysis by Type of Funding
  9.3.4. Analysis by Amount Invested across Different Types of Therapies
  9.3.5. Analysis by Amount Invested across Different Types of Indications
  9.3.4. Analysis by Geography
  9.3.5. Most Active Players: Analysis by Amount of Funding
  9.3.6. Most Active Investors: Analysis by Number of Instances
9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies Market, 2019-2030
  10.3.1. Global Neoantigen Targeted Therapies Market: Distribution by Region, 2019-2030 (USD Million)
  10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    10.3.2.1. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
    10.3.2.2. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
    10.3.2.3. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
    10.3.2.4. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
    10.3.2.5. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
    10.3.2.6. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
    10.3.2.7. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
    10.3.2.8. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
  10.3.3. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    10.3.3.1. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted Therapies, 2019-2030 (USD Million)
    10.3.3.2. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted Therapies, 2019-2030 (USD Million)
  10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    10.3.4.1. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
    10.3.4.2. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
    10.3.4.3. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines, 2019-2030 (USD Million)
    10.3.4.4. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
  10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
    10.3.5.1. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
    10.3.5.2. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
    10.3.5.3. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
    10.3.5.4. Global Neoantigen Targeted Therapies Market for Other Routes of Administration, 2019-2030 (USD Million)
10.4. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
  10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
10.5. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
  10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
10.6. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
  10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
10.7. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
  10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
10.8. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
  10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
10.9. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
  10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
10.10. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
  10.10.1. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  10.10.2. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  10.10.3. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  10.10.4. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

12.1. Chapter Overview
12.2. AIVITA Biomedical
  12.2.1. Company Snapshot
  12.2.2. Interview Transcript: Gabriel Nistor (Chief Scientific Officer)
12.3. BioLineRx
  12.3.1. Company Snapshot
  12.3.2. Interview Transcript: Ella Sorani (Vice President Research and Development)
12.3. VAXIMM
  12.3.1. Company Snapshot
  12.3.2. Interview Transcript: Heinz Lubenau (Chief Operating Officer and Co-Founder)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS